Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to acceler ...

Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief ...

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

The mammalian immune system is an evolutionary wonder. It's capable of recognizing and destroying cancer cells, and it can ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...